Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HTR1A | P08908 | 8/20 | 0.58 |
| ▸ | HTR2B | P41595 | 2/20 | 0.58 |
| ▸ | HTR1D | P28221 | 1/20 | 0.58 |
| ▸ | ADRA1A | P35348 | 5/20 | 0.56 |
| ▸ | DRD2 | P14416 | 2/20 | 0.56 |
| ▸ | DRD3 | P35462 | 2/20 | 0.56 |
| ▸ | DRD4 | P21917 | 3/20 | 0.51 |
| ▸ | ADRA1D | P25100 | 3/20 | 0.51 |
| ▸ | ADRA1B | P35368 | 3/20 | 0.51 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.51 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.51 |
| ▸ | TSHR | P16473 | 1/20 | 0.51 |
| ▸ | HTR1B | P28222 | 1/20 | 0.51 |
| ▸ | HTR7 | P34969 | 1/20 | 0.51 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5858332 | 0.88 | HTR1A (0.44) | HTR1AHTR2BHTR1DADRA1ADRD2 | |
| SCHEMBL5475907 | 0.87 | HTR1A (0.52) | HTR1AHTR2BHTR1DADRA1ADRD2 | |
| SCHEMBL5475905 | 0.87 | HTR1A (0.52) | HTR1AHTR2BHTR1DADRA1ADRD2 | |
| SCHEMBL5372555 | 0.87 | HTR1A (0.73) | HTR1AHTR2BHTR1DADRA1ADRD2 | |
| SCHEMBL5389828 | 0.87 | HTR1A (0.73) | HTR1AHTR2BHTR1DADRA1ADRD2 | |
| SCHEMBL5473416 | 0.86 | HTR1A (0.51) | HTR1AHTR2BHTR1DADRA1ADRD2 | |
| SCHEMBL5473410 | 0.86 | HTR1A (0.51) | HTR1AHTR2BHTR1DADRA1ADRD2 | |
| SCHEMBL5478896 | 0.86 | HTR1A (0.51) | HTR1AHTR2BHTR1DADRA1ADRD2 | |
| SCHEMBL5478890 | 0.86 | HTR1A (0.51) | HTR1AHTR2BHTR1DADRA1ADRD2 | |
| Hydrochloric Acid SCHEMBL6435545 | 0.86 | HTR1A (0.72) | HTR1AHTR2BHTR1DADRA1ADRD2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20070270436-A1 | NOVEL AMINO- AND IMINO-ALKYLPIPERAZINES | RECORDATI IRELAND LIMITED (IE) | 2007-11-22 | — | — | US | disclosed |
| US-20060148821-A1 | N,N-disubstituted diazocycloalkanes | RECORDATI S.A. (CH) | 2006-07-06 | — | — | US | disclosed |
| US-7071197-B2 | N,N-disubstituted diazocycloalkanes | RECORDATI S.A. (CH) | 2006-07-04 | — | — | US | disclosed |
| EP-1549627-A1 | 1-PHENYLALKYL-PIPERAZINES | Recordati Ireland Limited (IE) | 2005-07-06 | — | — | EP | disclosed |
| US-20040072822-A1 | N,N-disubstituted diazocycloalkanes | RECORDATI S.A. (CH) | 2004-04-15 | — | — | US | disclosed |
| US-20040072839-A1 | 1-Phenylalkylpiperazines | RECORDATI S.A. (CH) | 2004-04-15 | — | — | US | disclosed |
| WO-2003106443-A1 | 1-PHENYLALKYL-PIPERAZINES | RECORDATI S.A. (CH) | 2003-12-24 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040072822-A1 | N,N-disubstituted diazocycloalkanes | HTR1D, HTR1A, HTR2C | HTR1A 2/4885HTR2B 27/4885HTR1D 1/4885 |
| US-20040072839-A1 | 1-Phenylalkylpiperazines | HTR5A, HTR1A, HTR1D | HTR1A 2/4885HTR2B 11/4885HTR1D 3/4885 |
| US-20070270436-A1 | NOVEL AMINO- AND IMINO-ALKYLPIPERAZINES | HTR5A, HTR1A, HTR2C | HTR1A 2/4885HTR2B 9/4885HTR1D 6/4885 |
| US-20060148821-A1 | N,N-disubstituted diazocycloalkanes | HTR1A, HTR1D, HTR2C | HTR1A 1/4885HTR2B 22/4885HTR1D 2/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.